Adam S Kittai, MD

Icahn School of Medicine at Mount Sinai

Poster(s):

• 1411 - Outcomes, inequities, and access to front-line preferred therapies for chronic lymphocytic leukemia in the United States: a real-world evidence study

• 1801 - Targeting BTKi-Resistant CLL Using the Dual Irreversible/Reversible 4th Generation BTK Inhibitor Rocbrutinib